Representative figures of immunohistochemistry in adenocarcinoma show that high YTHDF1 or YTHDF2 cases are associated with low CD4, CD8 and high FOXP3 expression in both PD-1 inhibitor treatment and non-treatment groups (Figure 3). This evidence concerns the gene CD4 and adenocarcinoma.